With facilities in MA and in CA, EnVivo Pharmaceuticals Inc had been named one of the "Fierce 15" Leading Biotech Companies and drew a management team from the full complement of lead players in the bio tech space. Committed to the discovery and long-term development of innovative drugs that would improve function and change the course of disease in patients with dementias, schizophrenia and other neuropsychiatric disorders, the approach was multi-target and multi-program by design. EnVivo built a robust and diverse pipeline focused on important neuropsychiatric conditions for which currently available therapies are insufficient and leave profound unmet needs. Renamed Forum Pharmaceuticals somewhere along the way, the firm was well financed - the primary investor was Fidelity Biosciences, now called F-Prime Capital reported as pouring hundreds of millions of dollars into the company over the years and becaming Forumâs sole owner in 2008 - and with a highly experienced team, the firm was strongly positioned to develop and commercialize their own programs. In fact, in light of the failure of two of the firm's lead products in clinical trials in June 2016, FORUM Pharma closes Its door
